This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2- breast cancer, highlighting their mechanisms, interaction with endocrine resistance, combination strategies, and emerging biomarkers guiding personalized therapy. The gene discussed is CDK4; the disease is breast cancer.